FDA says Cannabinoid Blocker Not safe for Human Consumption

Puffin Tuff · 06-17-2007, 09:36 PM

Quote:

FDA Advisory Panel Says Controversial Cannabinoid Blocker Not Safe For Human Consumption

June 14, 2007 - Rockville, MD, USA

Rockville, MD: An independent Food and Drug Administration (FDA) advisory committee determined on Wednesday that the controversial cannabinoid receptor antagonist Rimonabant (also known as Acomplia) is unsafe for human consumption in the United States. The drug's manufacturer, Sanofi-Aventis Pharmaceuticals, is seeking FDA approval to market the drug in the US as a dietary aid.

Members of the FDA's Endocrinologic and Metabolic Drug advisory panel resolved 14-0 that the drug did not possess a "favorable risk-benefit profile" to warrant US regulatory approval. Panelists reported that patients prescribed Rimonabant experienced increased incidences of depression, nausea, vomiting, and suicidal tendencies. Adverse neurological symptoms, including multiple sclerosis, have also been documented in subjects who have taken Rimonabant.

European regulators previously approved the prescription use of Rimonabant, marketed under the trade name Acomplia, in 2006 but are now expected to review their decision. Rimonabant is the first cannabinoid antagonist ever to be approved for human consumption. More than 100,000 European patients have been prescribed Acomplia since its approval last year.

The FDA is expected to make a final ruling regarding whether to approve or reject the drug in July. The agency typically abides by the recommendations of its advisory panels, but it is not legally required to do so.

Rimonabant blocks the natural binding of endogenous cannabinoids (as well as exogenous cannabinoids such as THC) to the neuronal CB1 receptors, causing users to lose their appetites. However, because the endocannabinoid receptor system is intricately involved in the regulation of a broad range of primary biological functions – including appetite, body temperature, mood regulation, blood pressure, bone density, reproduction, learning capacity, and motor coordination – some experts are concerned that the long-term use of Rimonabant or similar drugs may contribute to a host of significant adverse health effects.

In preclinical trials, newborn mice injected with Rimonabant refuse feeding and often die days after birth. Mice genetically bred to lack the CB1 receptor also suffer from numerous health defects such as cognitive decline, hypoalgesia, decreased locomotor activity, and increased mortality compared to healthy controls.

At least one published case study reports that daily use of the drug may have triggered neurological symptoms of multiple sclerosis in a volunteer with no known history of the disease. Mental health side effects, such as depression, are also commonly reported among volunteers administered Rimonabant. FDA panelists reported that using Rimonabant nearly doubled the users risk of attempting suicide.

The FDA has previously rejected requests by Sanofi-Aventis to approve the drug as a smoking cessation agent.

Spirit of Bear · 06-17-2007, 11:02 PM

>>>Rimonabant blocks the natural binding of endogenous cannabinoids (as well as exogenous cannabinoids such as THC) to the neuronal CB1 receptors, causing users to lose their appetites. However, because the endocannabinoid receptor system is intricately involved in the regulation of a broad range of primary biological functions – including appetite, body temperature, mood regulation, blood pressure, bone density, reproduction, learning capacity, and motor coordination – some experts are concerned that the long-term use of Rimonabant or similar drugs may contribute to a host of significant adverse health effects.<<<

Sounds like a bit of THC is healthy for you, lol.........

SOB

ioneyesus · 06-18-2007, 07:48 AM

who wrote this crap? Norml? Damn they need to hire new reporters...

"In preclinical trials, newborn mice injected with Rimonabant refuse feeding and often die days after birth. Mice genetically bred to lack the CB1 receptor also suffer from numerous health defects such as cognitive decline, hypoalgesia, decreased locomotor activity, and increased mortality compared to healthy controls."

What the hell does this have to do with a temporary antagonist that adult humans use? NOTHING! Did the FDA do more than glance at this research while looking for human data? HELL NO! Ridiculous they would say this bullshit instead of delving more into the effects noted in clinical trials. Then they throw some hearsay in there about a patient 'who had symptoms of MS.' According to who? This is disgusting propaganda just cause it outbinds THC. NORML makes more of a problem instead of working towards a solution by putting out propaganda nearly as bad as the anti pot garbage.

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
FDA Postpones Decision On Safety Of Controversial Cannabinoid Blocking Agent	ZoomBoom	Latest News	0	04-06-2007 01:32 PM
Human Blood	Twich	Organics	11	08-15-2004 03:36 AM
Human pee as fert	Mookie	Organics	9	10-23-2003 10:38 PM
Macro of THC molecule for your perusal, + cannabinoid info.	ommamedmar	Theories & Speculation	2	12-03-2002 02:54 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Privacy Statement Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)

Hot Products: